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MaOBJECTIVES This study was performed to determine whether a 4-tiered classiﬁcation of left ventricular hypertrophy
(LVH) deﬁnes subgroups in the general population that are at variable risks of adverse cardiovascular (CV) outcomes.
BACKGROUND We recently proposed a 4-tiered classiﬁcation of LVH where eccentric LVH is subdivided into
“indeterminate hypertrophy” and “dilated hypertrophy” and concentric LVH into “thick hypertrophy” and “both thick
and dilated hypertrophy,” based on the presence of increased left ventricular (LV) end-diastolic volume.
METHODS Participants from the Dallas Heart study who underwent cardiac magnetic resonance and did not have LV
dysfunction or a history of heart failure (HF) (n ¼ 2,458) were followed for a median of 9 years for the primary outcome
of HF or CV death. Multivariable Cox proportional hazards models were used to adjust for age, sex, African-American
race, hypertension, diabetes, and history of CV disease.
RESULTS In the cohort, 70% had no LVH, 404 (16%) had indeterminate hypertrophy, 30 (1%) had dilated hypertrophy,
289 (12%) had thick hypertrophy, and 7 (0.2%) had both thick and dilated hypertrophy. The cumulative incidence of HF
or CV death was 2% with no LVH, 1.7% with indeterminate, 16.7% with dilated, 11.1% with thick, and 42.9% with both
thick and dilated hypertrophy (log-rank p < 0.0001). Compared with participants without LVH, those with dilated
(hazard ratio [HR]: 7.3; 95% conﬁdence interval [CI]: 2.8 to 18.8), thick (HR: 2.4; 95% CI: 1.4 to 4.0), and both thick and
dilated (HR: 5.8; 95% CI: 1.7 to 19.5) hypertrophy remained at increased risk for HF or CV death after multivariable
adjustment, whereas the group with indeterminate hypertrophy was not (HR: 0.9; 95% CI: 0.4 to 2.2).
CONCLUSIONS In the general population, the 4-tiered classiﬁcation system for LVH stratiﬁed LVH into subgroups with
differential risk of adverse CV outcomes. (J Am Coll Cardiol Img 2015;8:1034–41) © 2015 by the American College of
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AB BR E V I A T I O N S
AND ACRONYM S
BSA = body surface area
CI = conﬁdence interval
CMR = cardiac magnetic
resonance
CV = cardiovascular
EDV = end-diastolic volume
HF = heart failure
HR = hazard ratio
hs-cTnT = high-sensitivity
cardiac troponin T
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1035linear dimensions for wall thickness and chamber
size and not accounting for LV dilation in isolation,
an important aspect of geometric remodeling.
We have previously proposed a 4-tiered classiﬁca-
tion of LVH based on LV end-diastolic volume (EDV)
and concentricity (a marker of wall thickness) as
assessed by cardiac magnetic resonance (CMR) (6). In
this classiﬁcation, eccentric hypertrophy was further
divided into dilated hypertrophy and indeterminate
hypertrophy based on whether the LV volume was
increased. Similarly, concentric hypertrophy was
divided into thick hypertrophy and both thick and
dilated hypertrophy (Figure 1) (6).SEE PAGE 1042
LV = left ventricular
LVH = left ventricular
hypertrophyIn our initial cross-sectional description of this
classiﬁcation system, we demonstrated clear pheno-
typic differences between the 2 newly proposed
subcategories of both eccentric and concentric hy-
pertrophy. Those with dilated hypertrophy were
more likely to have elevated levels of natriuretic
peptides and lower LV ejection fraction (EF) than
those with indeterminate hypertrophy. Similarly,
those with both thick and dilated hypertrophy had a
higher prevalence of reduced LVEF than those with
isolated thick hypertrophy. Subsequent studies have
related the 4-tiered classiﬁcation system to clinical
outcomes in patients with hypertension and coronary
artery disease (7,8). However, these studies used
echocardiography, which has known limitations in
assessing LV mass and LV volume when compared
with CMR (5,9). Moreover, this classiﬁcation system
has not yet been related to clinical outcomes in an
unselected general population sample.
Therefore, we classiﬁed participants from the
Dallas Heart Study with the 4-tiered classiﬁcation
system for LVH using CMR and determined associa-
tions of the 4-tiered subgroups with incident heart
failure (HF) and CV death. In addition, we compared
levels of high-sensitivity cardiac troponin T (hs-cTnT),
a marker of cardiac injury shown to be associated with
HF and death (10–12), across the subgroups.
METHODS
STUDY POPULATION. The Dallas Heart Study is a
multiethnic, population-based, cohort study of Dallas
County adults in which deliberate oversampling of
African Americans was performed. The design and
detailed methods of the Dallas Heart Study have been
previously described (13). In brief, the study was
conducted in 3 visits. Visit 1 was an initial in-home
visit (n ¼ 6,101) in which demographics, medical
history, and blood pressure were obtained. This wasfollowed by collection of fasting blood and
urine samples at a second in-home visit (n ¼
3,557). Visit 3 was conducted on the campus of
University of Texas Southwestern Medical
Center, during which detailed imaging studies
including CMR were performed (n ¼ 2,803).
Participants were subsequently followed
for pre-deﬁned clinical events and death. For
this study, we excluded participants with a
LVEF<40% and those with a clinical history of
HF at baseline, resulting in a ﬁnal cohort of
2,458 participants. Written informed consent
was provided by all participants, and the Uni-
versity of Texas Southwestern Institutional
Review Board approved the study.
CMR. CMRwas performed using 2 comparable
1.5-T systems (Phillips Medical Systems, Best, the
Netherlands). As previously described, mass and vol-
ume measurements were calculated from short-axis
breath-hold electrocardiography-gated cine CMR
and MASS software (Medis Medical Imaging Systems,
Leiden, the Netherlands) was used to analyze data
(14). The papillary muscles were included in the
mass of the left ventricle. The mean wall thickness of
the left ventricle was determined by averaging thewall
thickness of each slice, excluding the apical slice.
Further details of the CMR protocol have been previ-
ously published including intraobserver, interob-
server, and interscan variability (14,15).
DEFINITIONS. For the primary analysis, LVH was
classiﬁed as increased LV mass when indexed to
height2.7 using thresholds of $48 g/m2.7 for men
and $39 g/m2.7 for women (14). A sensitivity analysis
was performed indexing LV mass to body surface
area (BSA) using thresholds of $112 g/m2 for
men and $89 g/m2 for women. LV concentricity0.67
was deﬁned as LV mass/LV end-diastolic volume
(EDV)0.67, as previously described (6). Previously
deﬁned thresholds for elevated LVEDV indexed to
BSA ($74 ml/m2 for men and $68 ml/m2 for women)
and LV concentricity0.67 ($9.1 g/ml0.67 for men
and $8.9 g/ml0.67 for women) were used (6). The 4
categories of LVH were: 1) indeterminate hypertro-
phy (neither increased concentricity0.67 nor increased
LVEDV/BSA); 2) dilated hypertrophy (increased
LVEDV/BSA without increased concentricity0.67);
3) thick hypertrophy (increased concentricity0.67
without increased LVEDV/BSA); and 4) both thick and
dilated hypertrophy (increased concentricity0.67 and
LVEDV/BSA). To contrast the 4-tiered classiﬁcation
with the prior 2-tiered classiﬁcation, we deﬁned LVH
in the 2-tiered classiﬁcation as concentric when
concentricity0.67 was increased and eccentric when
concentricity0.67 was not increased (6).
FIGURE 1 Schematic of Standard 2-Tier and 4-Tier Classiﬁcation for LVH
Both of the standard 2-tiered subgroups are subclassiﬁed based on the presence of
increased indexed LV volume. Reprinted with permission from Khouri et al. (6). BSA ¼ body
surface area; EDV ¼ end-diastolic volume; LV ¼ left ventricular; LVH ¼ left ventricular
hypertrophy.
Garg et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 8 , N O . 9 , 2 0 1 5
LV Geometry, Troponin, and Outcome S E P T E M B E R 2 0 1 5 : 1 0 3 4 – 4 1
1036Hs-cTnT (Elecys-2010 Troponin T hs STAT, Roche
Diagnostics, Indianapolis, Indiana) was measured
from baseline samples as previously described (10).
Elevated hs-cTnT was deﬁned as equal to or greater
than the limit of blank of the assay (>3 ng/l).
OUTCOMES. The primary outcome was the composite
of incident HF or CV death. Incident HF was deﬁned
as ﬁrst hospitalization for HF with reduced or pre-
served EF. A blinded endpoint committee adjudicated
nonfatal CV events (including HF). The secondary
endpoints were CV death alone and incident
HF alone. Death events were determined through
December 31, 2010, from the National Death Index
and classiﬁed as cardiovascular based on the
International Classiﬁcation of Diseases-10 codes I00
to I99 (16).
STATISTICAL ANALYSIS. Statistical comparisons of
variables among the 4 groups—indeterminate,
dilated, thick, and both thick and dilated—were done
using the chi-square test for dichotomous variables
and Wilcoxon rank sum test for continuous variables.
No adjustments were made for multiple comparisons.
The incidence of the primary outcome among each
group was estimated using Kaplan-Meier analysis.
Multivariable Cox proportional hazards models were
used to adjust for age, sex, African-American race,
hypertension, diabetes, and history of CV disease.
Because of the limited number of events, secondaryendpoints of CV death alone and incident HF alone
were not adjusted. Four sensitivity analyses were
performed, including repeating the primary analyses
using LVH deﬁned by LV mass indexed to BSA; using
the continuous parameter of systolic blood pressure
instead of hypertension as a covariate; including
body mass index as a covariate; and repeating the
primary analysis after further excluding all patients
with a baseline history of CV disease. All statistical
analyses were performed with SAS version 9.1 (SAS
Institute, Inc., Cary, North Carolina) statistical soft-
ware and all p values are 2-sided with an alpha of
0.05.
RESULTS
The baseline characteristics of the study cohort are
shown in Table 1, stratiﬁed by the 4-tiered classiﬁca-
tion system for LVH. Among the 2,458 participants
meeting study criteria (mean age 44 years; 56%
women, 48% African American), 730 (30%) had LVH,
of whom 404 were classiﬁed as indeterminate,
30 as dilated hypertrophy, 289 as isolated thick hy-
pertrophy, and 7 as having both thick and dilated
hypertrophy. In the study group, 773 (31%) of the
participants had hypertension and 245 (10%) had
diabetes, with a higher proportion of hypertension
and diabetes seen in the participants with isolated
thick and both thick and dilated LVH.
When using the standard 2-tiered LVH classiﬁca-
tion, the prevalence of detectable hs-cTnT in parti-
cipants with eccentric LVH was lower compared
with those without LVH (18% vs. 24%, p ¼ 0.005)
(Figure 2A). In contrast, when eccentric hypertrophy
was subdivided in the 4-tiered classiﬁcation
(Figure 2B), the dilated subgroup had a higher prev-
alence of detectable hs-cTnT (43%) as compared with
those without LVH (24%, p ¼ 0.02) or those with
indeterminate hypertrophy (16%, p ¼ 0.0004). Simi-
larly, subjects with both thick and dilated hypertro-
phy were more likely to have elevated hs-cTnT than
those with isolated thick hypertrophy (100% vs. 42%,
p ¼ 0.002).
Over a median follow up period of 9.1 (interquartile
range: 8.6 to 9.6) years, the primary composite
outcome of incident HF or CV death occurred in 81
(3.3%; 95% conﬁdence interval [CI]: 2.6 to 4.1) par-
ticipants, including 35 HF events and 47 CV deaths. In
the 2-tiered classiﬁcation system, the cumulative
incidence of HF or CV death in participants with
concentric LVH was 11.8% (95% CI: 8.1 to 15.6)
compared with 2.8% (95% CI: 1.2 to 4.3) in the
eccentric LVH group and 2.0% (95% CI: 1.3 to 2.7) in
the group with no LVH (log-rank p < 0.0001).













Age, yrs 43 (36, 52) 43 (36, 51) 43 (35, 46) 49 (42, 56)* 53 (46, 58)
Men 52 14* 43 41* 86
Black 41 55* 73* 79* 71
BMI, kg/m2 28 (24, 31) 35 (31, 40)* 27 (24, 35) 34 (30, 40)* 33 (29, 45)†
Hypertension 23 37 37 74* 86*
SBP, mm Hg 122 (112, 131) 125 (115, 138)* 131 (122, 141)† 141 (128, 155)* 145 (128, 159)†
DBP, mm Hg 76 (71, 82) 79 (73, 85)* 76 (74, 83) 85 (78, 92)* 86 (76, 89)
Diabetes 7 11 7 24* 57*
CVD 3 3 3 10* 14
eGFR, ml/min/1.73 m2 96 (84, 109) 103 (91, 116)* 111 (95, 136)* 95 (82, 110) 97 (81, 111)
LVEF, % 73 (68, 77) 75 (71, 80)* 72 (59, 76) 72 (67, 78) 62 (45, 76)
LV mass/height2.7 36 (32, 40) 44 (41, 49)* 53 (48, 60)* 52 (47, 57)* 66 (64, 69)*
LV mass/BSA, g/m2 77 (67, 89) 78 (73, 86)* 109 (93, 126)* 100 (86, 116)* 144 (125, 146)*
LVEDV/BSA, ml/m2 51 (45, 57) 53 (48, 58)* 81 (71, 92)* 48 (41, 56)* 80 (74, 88)*
Concentricity0.67, g/ml0.67 7 (6, 8) 7 (7, 8) 7 (6, 8) 10 (9, 11)* 10 (9, 10)*
LV wall thickness, mm 11 (10, 12) 11 (11, 12)* 12 (11, 13)† 14 (13, 15)* 15 (15, 16)*
Values are median (25%, 75% percentile) or %. *p < 0.001 versus no LVH group. †p < 0.01 versus no LVH group.
BMI ¼ body mass index; BSA ¼ body surface area; CVD ¼ cardiovascular disease; DBP ¼ diastolic blood pressure; eGFR ¼ estimated glomerular ﬁltration rate; LV ¼ left ventricular; LVEDV ¼ left ventricular
end-diastolic volume; LVEF ¼ left ventricular ejection fraction; LVH ¼ left ventricular hypertrophy; SBP ¼ systolic blood pressure.
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1037No signiﬁcant difference in the primary endpoint was
seen between the eccentric LVH and no LVH groups
(p ¼ 0.31) (Figure 3A). In the 4-tiered classiﬁcation
system, the cumulative incidence of HF or CV death
was 2.0% (95% CI: 1.3 to 2.7) with no hypertrophy,
1.7% (95% CI: 0.47 to 3.0) with indeterminate hyper-
trophy, 16.7% (95% CI: 3.0 to 30.4) with dilated hy-
pertrophy, 11.1% (95% CI: 7.4 to 14.8) with isolated
thick hypertrophy, and 42.9% (95% CI: 6.2 to 79.5) in
those with both thick and dilated hypertrophy
(log-rank p < 0.0001) (Figure 3B). There was no sig-
niﬁcant difference in the risk of HF or CV death
between those with indeterminate hypertrophy and
those without LVH (p ¼ 0.74).
In multivariable analyses, using the 2-tiered clas-
siﬁcation, those with concentric LVH but not eccen-
tric were at increased risk of HF or CV death (Table 2).
When applying the 4-tiered classiﬁcation of LVH,
eccentric LVH was stratiﬁed into lower risk (indeter-
minate hypertrophy) and higher risk (dilated hyper-
trophy) subgroups. Speciﬁcally, as compared with
those without LVH, participants with indeterminate
hypertrophy were not at increased risk, whereas
those with dilated hypertrophy were at signiﬁcantly
increased risk of HF or CV death (Table 2). Similarly,
compared with participants with no LVH, isolated
thick hypertrophy and both thick and dilated hyper-
trophy remained associated with increased HF and
CV death (Table 2). Dilated hypertrophy wasassociated with increased risk compared with isolated
thick hypertrophy (hazard ratio [HR]: 3.1; 95% CI: 1.2
to 8.0). Dilated, thick, and both thick and dilated
hypertrophy remained independently associated with
adverse CV outcomes when hs-cTnT was added to the
multivariable adjustment (Table 2). Finally, the
continuous parameters of LVEDV (HR: 1.5; 95% CI: 1.2
to 1.9), LV wall thickness (HR: 1.4; 95% CI, 1.2 to 1.7),
and hs-cTnT (HR: 1.2; 95% CI: 1.02 to 1.5) were inde-
pendently associated with increased risk of HF or CV
death in multivariable analysis adjusted for age, sex,
African-American race, hypertension, diabetes, and
history of CV disease.
Secondary endpoints of incident HF alone and CV
death alone are shown in Table 3. In unadjusted
analysis, indeterminate hypertrophy was not associ-
ated with increased risk of either HF alone or CV
death alone when compared with no LVH. Thick,
dilated, and both thick and dilated hypertrophy were
associated with increased risk of incident HF
compared with no LVH. Thick hypertrophy and both
thick and dilated hypertrophy were associated with
increased risk of CV death alone.
In a sensitivity analysis in which LVH was deﬁned
based on LV mass indexed to BSA (Online Table 1),
there were no events among the 35 subjects with
indeterminate LVH, whereas dilated LVH remained
associated with the outcome in both unadjusted
(HR: 11.9; 95% CI: 4.7 to 30.1) and adjusted models
FIGURE 2 Prevalence of Elevated hs-cTnT
Prevalence of elevated hs-cTnT in the (A) 2-tiered and (B) 4-tiered classiﬁcation of LVH. *p < 0.001 versus no LVH group. †p < 0.02 versus no
LVH group. hs-cTnT ¼ high-sensitivity cardiac troponin T; LVH ¼ left ventricular hypertrophy.
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1038(HR: 8.3; 95% CI: 3.2 to 21.0). Similarly, thick and both
thick and dilated hypertrophy remained associated
with adverse CV outcomes (Online Table 1). Addi-
tional sensitivity analyses excluding participants
with a history of CV disease, using systolic blood
pressure as a covariate in place of hypertension,
and adjusting for body mass index revealed similar
associations (data not shown).
DISCUSSION
The present study demonstrates that individuals
from the general population with concentric or
eccentric LVH, as deﬁned by the standard 2-tieredFIGURE 3 Kaplan-Meier Curves for Incident HF or CV Death
Unadjusted Kaplan-Meier curves for incident HF or CV death stratiﬁed by (
HF ¼ heart failure; LVH ¼ left ventricular hypertrophy.classiﬁcation system, can be subclassiﬁed based on
the presence or absence of LV dilation into 2 further
subgroups with distinct longitudinal trajectories.
Participants with eccentric hypertrophy can be sub-
classiﬁed into a low-risk (indeterminate hypertrophy)
and a high-risk group (dilated hypertrophy). Simi-
larly, concentric hypertrophy can be divided into 2 at
risk groups: thick hypertrophy and both thick and
dilated hypertrophy.
In our initial description of the 4-tiered classiﬁca-
tion system, we demonstrated that participants with
indeterminate hypertrophy did not have a reduced
LVEF, elevated natriuretic peptides, or higher fre-
quency of detectable cTnT by conventional assayA) 2-tiered and (B) 4-tiered classiﬁcation of LVH. CV¼ cardiovascular;
TABLE 2 Unadjusted and Multivariable Adjusted Associations of 2- and 4-Tiered Classiﬁcation of LVH with Incident HF or CV Death








No LVH* 1,728 34 1.0 1.0 1.0
Eccentric LVH 434 12 1.4 (0.7–2.7) 1.5 (0.8–3.1) 1.4 (0.7–2.9)
Concentric LVH 296 35 6.3 (3.9–10.1) 2.5 (1.5–4.2) 2.2 (1.3–3.8)
4-Tiered
No LVH* 1,728 34 1.0 1.0 1.0
Indeterminate 404 7 0.9 (0.4–2.0) 0.9 (0.4–2.2) 0.9 (0.4–2.1)
Dilated 30 5 9.5 (3.7–24.2) 7.3 (2.8–18.8) 5.5 (2.0–14.9)
Thick 289 32 5.9 (3.6–9.5) 2.4 (1.4–4.0) 2.2 (1.3–3.7)
Both 7 3 26.8 (8.2–87.3) 5.8 (1.7–19.5) 4.6 (1.4–15.7)
LVH is indexed to height2.7. *Referent group. Adjusted hazard ratio includes adjustments for age, sex, race, diabetes, hypertension, and CVD. †Adjusted hazard ratio (HR) also
includes added adjustment for high-sensitivity cardiac troponin T.
CI ¼ conﬁdence interval; E ¼ number of events; n ¼ number of participants; other abbreviations as in Table 1.
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1039when compared with those without LVH (6). The
hs-cTnT assay is approximately 10-fold more sensi-
tive than the conventional assay in the assessment of
cardiac injury and has been strongly associated
with abnormalities in cardiac structure and function
and subsequent mortality (10,11). In our present
study, we found that participants with indeterminateTABLE 3 Unadjusted Associations of 2- and 4-Tiered
Classiﬁcation of LVH With Incident HF and CV Death
Unadjusted Incident HF
LVH Classiﬁcation n E HR (95% CI)
2-Tiered
No LVH* 1,728 7 1.0
Eccentric LVH 434 7 4.0 (1.4–11.3)
Concentric LVH 296 21 18.6 (7.9–43.7)
4-Tiered
No LVH* 1,728 7 1.0
Indeterminate 404 3 1.8 (0.5–7.0)
Dilated 30 4 37.2 (10.9–127.0)
Thick 289 18 16.2 (6.8–38.9)
Both 7 3 135.4 (34.9–524)
Unadjusted CV Death
LVH Classiﬁcation n E HR (95% CI)
2-Tiered
No LVH* 1,728 27 1.0
Eccentric LVH 434 5 0.7 (0.3–1.9)
Concentric LVH 296 15 3.3 (1.8–6.2)
4-Tiered
No LVH* 1,728 27 1.0
Indeterminate 404 4 0.6 (0.2–1.8)
Dilated 30 1 2.2 (0.3–16.1)
Thick 289 14 3.2 (1.7–6.0)
Both 7 1 9.6 (1.3–70.3)
LVH is indexed to height2.7. *Referent group.
Abbreviations as in Tables 1 and 2.hypertrophy had a lower prevalence of detectable
hs-cTnT and no increased risk of HF or CV death
compared with participants without hypertrophy.
Prior studies by others looking at the 4-tiered
classiﬁcation system assessed by echocardiography
have also shown that indeterminate hypertrophy was
not associated with adverse outcomes in individuals
with pre-existing hypertension or coronary artery
disease (7,8). CMR has improved accuracy and inter-
study reproducibility in the assessment of LV mass
(17,18). As such, our results provide further evidence
suggesting that indeterminate hypertrophy is a
benign phenotype, a ﬁnding that has important im-
plications given the strong association of indetermi-
nate hypertrophy with obesity, which is increasingly
prevalent in the population.
Recently, we showed that low circulating concen-
trations of hs-cTnT identify a malignant phenotype of
LVH (19). Here, we show that although dilated hy-
pertrophy, thick hypertrophy, and both thick and
dilated hypertrophy are each associated with detect-
able hs-cTnT, the association of these LV geometric
subtypes with adverse CV outcome persists despite
adjustment for hs-cTnT. This ﬁnding suggests that
both LV geometry and chronic subclinical myocardial
injury are important contributors to HF risk in the
population.
The risk of HF or CV death was increased in par-
ticipants with either dilated hypertrophy or both
thick and dilated hypertrophy. In addition, the
continuous parameter of LVEDV was independently
associated with increased risk of adverse CV out-
comes in multivariable analysis. These data, along
with previous reports of LV dilation alone being
associated with incident HF (20), conﬁrm the value of
reﬁning the phenotypic characterization of subjects
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
A 4-tiered classiﬁcation for LVH, which accounts for
increased LV wall thickness and EDV, can identify
subgroups of patients at differential risk of adverse CV
outcomes.
TRANSLATIONAL OUTLOOK: Additional studies
are needed to determine why individuals develop
different patterns of LV remodeling (i.e., thick hy-
pertrophy, dilated hypertrophy, or both thick and
dilated hypertrophy). Further work is also needed to
determine the pathophysiological links between sub-
clinical myocardial injury, LV geometry, and subse-
quent adverse clinical events including the
development of HF.
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1040with increased LV mass based on the presence or
absence of LV dilation. Further, the presence of LV
dilation may identify a subpopulation of patients
with LVH that may beneﬁt from aggressive preven-
tion and treatment to improve CV outcomes.
STUDY LIMITATIONS. The number of HF and CV
death events is relatively few due to the low-
risk general population cohort that was studied.
The associations of increased risk seen in the partic-
ipants with both thick and dilated hypertrophy
should be considered preliminary given the low
number of participants and events in this subgroup.
The National Death Index was used to ascertain CV
death, which may be inaccurate (21). Finally, our
study was limited to assessment of the role of LV
dilation among subgroups with LVH and does not
consider the role of LV dilation in the absence of LVH.
CONCLUSIONS
Compared with the standard 2-tiered classiﬁcation
system for LVH, the 4-tiered classiﬁcation system for
LVH identiﬁes subphenotypes of LVH in the general
population that are at variable risk of HF and CV
death. In particular, eccentric LVH can be stratiﬁed
based on the absence or presence of ventricular
dilation into a group at low risk (indeterminatehypertrophy) or high risk (dilated hypertrophy) for
these outcomes.
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